Literature DB >> 15182147

Surveillance of Mycobacterium tuberculosis susceptibility to second-line drugs in Hong Kong, 1995-2002, after the implementation of DOTS-plus.

K M Kam1, C W Yip.   

Abstract

OBJECTIVE: To determine the trend in changes in susceptibility of Mycobacterium tuberculosis strains, including to second-line drugs, from patients with a history of previous anti-tuberculosis (TB) treatment in a 'DOTS-Plus' programme.
METHODS: A retrospective survey of centralised M. tuberculosis laboratory records of all culture-positive cases over an 8-year period. The drug susceptibility of the isolates was determined using the absolute concentration method. Isolates obtained from patients with a history of previous treatment were further analysed for trends of changes in susceptibility to first- and second-line drugs.
RESULTS: Of 1921 patients with a previous history of treatment and positive cultures, 1425 (74.2%) had isolates susceptible to all four first-line drugs, while 176 (9.2%) were multidrug-resistant (MDR-TB). For the MDR-TB group, 101 (57.4%) isolates were sensitive to all second-line drugs, while 30 (17.0%) were resistant to three or more second-line drugs.
CONCLUSION: In a DOTS-Plus programme environment where there is strict control on use of second-line drugs, the prevalence of MDR-TB is low amongst retreatment cases and the prudent use of second-line drugs in a population with well functioning DOTS-Plus programme does not generate super-resistant strains. In circumstances where most retreatment strains are still susceptible and good laboratory support for detection of MDR cases is available, retreatment using first-line drugs is feasible.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15182147

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  9 in total

Review 1.  Multidrug-resistant to extensively drug resistant tuberculosis: what is next?

Authors:  Amita Jain; Pratima Dixit
Journal:  J Biosci       Date:  2008-11       Impact factor: 1.826

2.  Comparative study of intestinal tuberculosis and primary small intestinal lymphoma.

Authors:  Qing-Qiang Zhu; Wen-Rong Zhu; Jing-Tao Wu; Wen-Xin Chen; Shou-An Wang
Journal:  World J Gastroenterol       Date:  2014-04-21       Impact factor: 5.742

3.  Predictors of clinical and endoscopic findings in differentiating Crohn's disease from intestinal tuberculosis.

Authors:  Xuefeng Li; Xiaowei Liu; Yiyou Zou; Chunhui Ouyang; Xiaoping Wu; Minghuan Zhou; Linlin Chen; Lingjuan Ye; Fanggen Lu
Journal:  Dig Dis Sci       Date:  2010-05-14       Impact factor: 3.199

4.  The dragon and the tiger: realties in the control of tuberculosis.

Authors:  P Bhatter; A Chatterjee; N Mistry
Journal:  Interdiscip Perspect Infect Dis       Date:  2012-07-04

5.  Experiences in anti-tuberculosis treatment in patients with multiple previous treatments and its impact on drug resistant tuberculosis epidemics.

Authors:  Biao Xu; Qi Zhao; Yi Hu; Ying Shi; Weibing Wang; Vinod K Diwan
Journal:  Glob Health Action       Date:  2014-08-18       Impact factor: 2.640

6.  Strong decrease in streptomycin-resistance and absence of XDR 12 years after the Reorganization of the National Tuberculosis Control Program in the Central Region of Cameroon.

Authors:  Larissa Kamgue Sidze; Emmanuel Mouafo Tekwu; Christopher Kuaban; Jean-Paul Assam Assam; Jean-Claude Tedom; Sara Eyangoh; François-Xavier Fouda; Désiré Nolna; Francine Ntoumi; Matthias Frank; Véronique N Penlap Beng
Journal:  PLoS One       Date:  2014-06-05       Impact factor: 3.240

Review 7.  Extensively drug-resistant tuberculosis in India: Current evidence on diagnosis & management.

Authors:  Rajendra Prasad; Abhijeet Singh; Viswesvaran Balasubramanian; Nikhil Gupta
Journal:  Indian J Med Res       Date:  2017-03       Impact factor: 2.375

8.  Worldwide emergence of extensively drug-resistant tuberculosis.

Authors:  N Sarita Shah; Abigail Wright; Gill-Han Bai; Lucia Barrera; Fadila Boulahbal; Nuria Martín-Casabona; Francis Drobniewski; Chris Gilpin; Marta Havelková; Rosario Lepe; Richard Lumb; Beverly Metchock; Françoise Portaels; Maria Filomena Rodrigues; Sabine Rüsch-Gerdes; Armand Van Deun; Veronique Vincent; Kayla Laserson; Charles Wells; J Peter Cegielski
Journal:  Emerg Infect Dis       Date:  2007-03       Impact factor: 6.883

9.  Challenges and controversies in defining totally drug-resistant tuberculosis.

Authors:  Peter Cegielski; Paul Nunn; Ekaterina V Kurbatova; Karin Weyer; Tracy L Dalton; Douglas F Wares; Michael F Iademarco; Kenneth G Castro; Mario Raviglione
Journal:  Emerg Infect Dis       Date:  2012-11       Impact factor: 6.883

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.